Skip to main content
Kinarus Therapeutics Holding AG logo

Kinarus Therapeutics Holding AG — Investor Relations & Filings

Ticker · KNRS ISIN · CH1330780979 LEI · 506700VDL70GGMHR5758 SW Manufacturing
Open in API
Filings indexed 67 across all filing types
Latest filing 2026-05-23 Declaration of Voting R…
Country CH Switzerland
Listing SW KNRS

About Kinarus Therapeutics Holding AG

https://www.curatis.com/

Formerly Kinarus Therapeutics Holding AG, the company now operates as Curatis Holding AG, a specialty pharmaceutical company focused on the acquisition, development, and commercialization of innovative medicines for rare and specialty care diseases. The company's operations are divided into two segments. The distribution business acquires, licenses, and distributes third-party medicines for orphan and specialty diseases. The development business advances a pipeline of novel drug candidates, prioritizing compounds with existing safety and efficacy data to accelerate development. Key development programs target conditions such as peritumoral brain edema, severe migraine with aura, and medication overuse headache.

Recent filings

Filing Released Lang Actions
Annual General Meeting of Curatis Holding AG approved all proposals of the Board of Directors
Declaration of Voting Results & Voting Rights Announcements Classification · 89% confidence The document is a media release summarizing the outcome of Curatis Holding AG’s Annual General Meeting, including shareholder votes on board director elections, auditor re-election, and approval of resolutions. It announces voting results at the AGM, fitting the Definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-23 English
Curatis Holding AG announces CHF 3.0 million private placement with strategic investor
Capital/Financing Update Classification · 90% confidence The document is an ad-hoc announcement under Art. 53 LR describing a definitive agreement for a CHF 3.0 million private placement of a convertible instrument, i.e., a financing activity. It provides detailed terms of the fundraising and impact on the company’s capital structure. This clearly aligns with the Capital/Financing Update category rather than a regulatory notice or broader annual/interim report.
2026-05-22 English
Annual General Meeting of Curatis Holding AG approved all proposals of the Board of Directors
Declaration of Voting Results & Voting Rights Announcements Classification · 88% confidence The document is a media release summarizing the results of the Annual General Meeting, including shareholder votes on board proposals, auditor re-election, and compensation approvals. It reports the approval of all resolutions and lists re-elected board members. As it communicates the voting outcomes of a general meeting rather than providing the full meeting materials or financial statements, it fits the category for Declaration of Voting Results & Voting Rights Announcements.
2026-05-22 English
Curatis Holding AG announces CHF 3.0 million private placement with strategic investor
Capital/Financing Update Classification · 91% confidence The document is an ad hoc announcement under Swiss Listing Rule Art. 53 disclosing a CHF 3.0 million private placement (convertible instrument) capital increase with a strategic investor. This is a fundraising transaction and a change in the company’s capital structure. It is not a report publication notice but a financing update. Therefore it fits the “Capital/Financing Update” category.
2026-05-22 English
Articles of Incorporation
Governance Information Classification · 85% confidence The provided text is the Articles of Association (Statuten) of Curatis Holding AG/SA/Ltd, detailing the company’s internal rules on share capital, conditional capital, board authorizations, and corporate governance structure. It is not a financial report, earnings release, or proxy statement, but rather corporate charter/governance documentation. This aligns with Governance Information (CGR).
2026-04-07 German
Curatis: Double-digit revenue growth in 2025 and major milestones for corticorelin achieved
Earnings Release Classification · 88% confidence The document is an ad hoc press release under Swiss listing rules providing key full-year 2025 financial results (revenues, net result, cash position) and guidance for 2026. It is not the full annual report but a summary of financial highlights and outlook, consistent with an Earnings Release rather than a detailed annual report or management discussion. Therefore it best fits the Earnings Release category (ER). FY 2025
2026-03-24 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.